RESEARCH ARTICLE


New UV Spectrophotometric Method for the Estimation of Molnupiravir used in the treatment of COVID-19



Mahesh Deshpande1, *, Farhat Shaikh1
1 Department of Pharmaceutical Quality Assurance, Amrutvahini College of Pharmacy, Sangamner, Ahmednagar, Maharashtra, India


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 194
Abstract HTML Views: 102
PDF Downloads: 155
ePub Downloads: 65
Total Views/Downloads: 516
Unique Statistics:

Full-Text HTML Views: 123
Abstract HTML Views: 90
PDF Downloads: 116
ePub Downloads: 57
Total Views/Downloads: 386



Creative Commons License
© 2023 Deshpande et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Pharmaceutical Quality Assurance, Amrutvahini College of Pharmacy, Sangamner, Ahmednagar, Maharashtra, India; E-mail: mahesh_deshpande11@rediffmail.com


Abstract

Background:

Antiviral drugs gained more importance due to SARS-COV-2 infection and many drugs are under investigation to end the pandemic. Molnupiravir is an investigational medicinal product being developed by Merck Sharp and Dohme in collaboration with Ridgeback for the treatment of COVID-19.

Objective:

A new, simple, and economical UV-spectrometric method was developed and validated for the estimation of Molnupiravir in a bulk and pharmaceutical dosage form.

Methods:

The maximum wavelength was found to be 236 nm. The developed method was validated according to ICH guidelines and found to be linear within the range of 10-50µg/ml with a correlation coefficient (R2) 0.9989.

Results:

The %RSD for precision, accuracy, LOD, LOQ, Ruggedness, and Robustness were within the range of acceptable limits as per ICH Q2 (R1). The accuracy of the method was determined at three concentration levels and found to be 99.87%, 99.53%, and 99.84%.

Conclusion:

All parameters obtained are within acceptable limits as per ICH guidelines. The molnupiravir was exposed to thermal, photolytic, hydrolytic, and oxidative stress conditions and its stability data was determined which will be useful for further formulation development.

Keywords: Molnupiravir, COVID-19, Spectrophotmetric, Stability, ICH, [Q2 (R1)].